Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OncoMyx Therapeutics

Request full access

Gene therapy with myxoma viruses

Tempe, United StatesFounded 2018Biotech & Life Sciences

About OncoMyx Therapeutics

OncoMyx Therapeutics operates in the biotechnology sector, focusing on developing oncolytic immunotherapies to treat cancer. The company leverages the myxoma virus, a type of virus that selectively infects and kills cancer cells while sparing normal cells. This innovative approach aims to enhance the body's immune response against tumors. OncoMyx primarily serves the healthcare market, targeting oncology patients and medical professionals seeking advanced cancer treatments. The business model revolves around research and development, clinical trials, and eventual commercialization of their therapies. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies. The company is positioned to address a significant unmet need in cancer treatment, offering a novel solution that could complement existing therapies and improve patient outcomes.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2018
Headquarters
Tempe, United States
Employees
3
Open positions
None listed
Dealroom signal
72.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Dec 2021 $50M $200M Boehringer Ingelheim Venture Fund · Xeraya Capital · Delos Capital · City Hill Ventures ↗
SERIES AOther financing Apr 2019 $25M $100M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

OncoMyx Therapeutics website traffic

Latest recorded traffic for OncoMyx Therapeutics is 240 monthly website visits, down 61.9% over the last three months. OncoMyx Therapeutics's team grew 0% over the past year.

Latest monthly visits240 3-month web change-61.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

OncoMyx Therapeutics in the Tempe ecosystem

Live from Dealroom

The OncoMyx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • B Capital
  • Lumira Ventures
  • Boehringer Ingelheim Venture Fund
  • Xeraya Capital
  • Delos Capital
  • City Hill Ventures
  • LYZZ Capital
  • Korea Investment Partners
  • Madison Partners

Other known investors1 additional known investor

  • Arizona State University
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Tempe HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OncoMyx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OncoMyx Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.